Rhino-Conjunctivitis - Pipeline Review, H1 2018

  • ID: 4576080
  • Report
  • 76 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • ALK-Abello AS
  • Allergy Therapeutics Plc
  • ASIT Biotech SA
  • Astellas Pharma Inc
  • Bial - Portela & Ca SA
  • Faes Farma SA
  • MORE
Rhino-Conjunctivitis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Rhino-Conjunctivitis - Pipeline Review, H1 2018, provides an overview of the Rhino-Conjunctivitis (Ophthalmology) pipeline landscape.

Rhinitis is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), and itching of the nose or eyes. It may be allergic or non-allergic. It is important to enact environmental control measures to avoid the allergens that are causing the problem.

Report Highlights:

This latest pipeline guide Rhino-Conjunctivitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhino-Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Phase II stages are 1, 9 and 8 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Rhino-Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rhino-Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rhino-Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rhino-Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rhino-Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ALK-Abello AS
  • Allergy Therapeutics Plc
  • ASIT Biotech SA
  • Astellas Pharma Inc
  • Bial - Portela & Ca SA
  • Faes Farma SA
  • MORE
Introduction

Report Coverage

Rhino-Conjunctivitis - Overview

Rhino-Conjunctivitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Rhino-Conjunctivitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rhino-Conjunctivitis - Companies Involved in Therapeutics Development

ALK-Abello AS

Allergopharma GmbH & Co KG

Allergy Therapeutics Plc

ASIT Biotech SA

Astellas Pharma Inc

Bial - Portela & Ca SA

Faes Farma SA

HAL Allergy BV

Laboratorios LETI SL

Oxagen Ltd

Rhino-Conjunctivitis - Drug Profiles

Acaroid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Rhinitis and Rhino conjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Birch Pollen Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Birch Pollen Induced Allergic Rhinitis and Rhino conjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Birch Pollen Induced Allergic Rhino conjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for House Dust Mite Induced Allergic Rhinitis and Rhino conjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhino conjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhino conjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergovac - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-4070 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bilastine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BM-41 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gp-ASIT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hdm-ASIT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pollinex Quattro Birch - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pollinex Quattro Grass - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

short ragweed pollen (Ambrosia artemisiifolia) allergen extract ODT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Timapiprant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rhino-Conjunctivitis - Dormant Projects

Rhino-Conjunctivitis - Discontinued Products

Rhino-Conjunctivitis - Product Development Milestones

Featured News & Press Releases

Feb 12, 2018: Completion of recruitment in PQ Grass Phase II trial

Jan 09, 2018: Allergy Therapeutics: PQ Birch Phase III clinical trial completes recruitment

Oct 19, 2017: Allergy Therapeutics: Commencement of dosing in PQ Grass Phase II Trial

May 30, 2017: ASIT biotech to disclose the detailed results of its phase III clinical study with gp-ASIT+ at EAACI 2017

Nov 30, 2015: Allergy Therapeutics Completes Patient Enrolment For Birch Study

May 18, 2014: BioTech Tools will be present at the EAACI congress

Jan 24, 2014: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the ragweed sublingual tablet

Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultra short Grass Allergy Vaccine by Allergy Therapeutics

Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites

Jan 24, 2012: Faes Farma announces bilastine's launch in Brazil

Nov 28, 2011: Allergy Therapeutics Submits Complete Response to PEI In Germany And Clinical Study Protocol To FDA

Oct 31, 2011: HAL Allergy Includes First Patient In Phase II PURETHAL Mites Study

Mar 29, 2011: Faes Farma markets bilastine under the brand Bilaxten in Spain

Dec 23, 2010: Faes Farma: Bilastine is Approved in Two Other Countries

Dec 02, 2010: Faes Farma: Bilastine is approved in eight European countries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Rhino-Conjunctivitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Rhino-Conjunctivitis - Pipeline by ALK-Abello AS, H1 2018

Rhino-Conjunctivitis - Pipeline by Allergopharma GmbH & Co KG, H1 2018

Rhino-Conjunctivitis - Pipeline by Allergy Therapeutics Plc, H1 2018

Rhino-Conjunctivitis - Pipeline by ASIT Biotech SA, H1 2018

Rhino-Conjunctivitis - Pipeline by Astellas Pharma Inc, H1 2018

Rhino-Conjunctivitis - Pipeline by Bial - Portela & Ca SA, H1 2018

Rhino-Conjunctivitis - Pipeline by Faes Farma SA, H1 2018

Rhino-Conjunctivitis - Pipeline by HAL Allergy BV, H1 2018

Rhino-Conjunctivitis - Pipeline by Laboratorios LETI SL, H1 2018

Rhino-Conjunctivitis - Pipeline by Oxagen Ltd, H1 2018

Rhino-Conjunctivitis - Dormant Projects, H1 2018

Rhino-Conjunctivitis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Rhino-Conjunctivitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • ALK-Abello AS
  • Allergopharma GmbH & Co KG
  • Allergy Therapeutics Plc
  • ASIT Biotech SA
  • Astellas Pharma Inc
  • Bial - Portela & Ca SA
  • Faes Farma SA
  • HAL Allergy BV
  • Laboratorios LETI SL
  • Oxagen Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll